VALIRX PLC

Board/Management Information • Dec 30, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0006T

ValiRx PLC

30 December 2016

ValiRx Plc

("ValiRx" or "the Company" or "the Group")

Yorkville CLN Conversion

London, UK., 29 December 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards commercialisation and partnering, announces that YA Global Master SPV Ltd ("Yorkville") has elected to convert a further portion of tranche 1 of the Convertible Loan Facility ("CLN").  Further details of the conversion are set out below.  The terms of the CLN were outlined in the announcement dated 2 September 2016.

Yorkville has elected to convert US$150,000 of tranche 1 CLNs (plus accrued interest of US$15,840) into 2,393,788 ordinary shares at a conversion price of 5.625p per share.

Following the conversion described above US$598,433 of tranche 1 CLNs and US$1,250,000 of tranche 2 CLNs remain outstanding.  The drawdown of the tranche 2 notes was announced on 2 December 2016.

Application for the 2,393,788 ordinary shares has been made to the London Stock Exchange and trading in these shares is expected to commence on or around 6 January 2017.

Following the issue of equity above the Company's issued share capital will comprise of 85,647,099 ordinary shares.

This announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

*** ENDS ***

For more information, please contact:

ValiRx plc	Tel: +44 (0) 20 3008 4416 www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.	Tel: +44 (0) 7879 458 364 [email protected]
Mark Treharne, Corporate Development Manager	Tel: +44 (0) 7736 564 686 [email protected]
Cairn Financial Advisers LLP (Nominated Adviser)	Tel: +44 (0) 20 7213 0883
Liam Murray / Jo Turner
Beaufort Securities Limited (Joint Broker)	Tel: +44 (0) 207 382 8300
Jon Belliss
Northland Capital Partners Limited (Joint Broker)	Tel: +44 (0) 203 861 6625
John Howes / Abigail Wayne (Broking)

Notes for Editors

ValiRx Plc

ValiRx is a biotechnology oncology focussed company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOELLFIDFILAFIR